I guess we should not be focusing on what is, but what will be.
~ The heparin sales will generate more profit than cochlear announced yesterday. There are no costs to acl anymore for this, just milestone payments & then royalties. The have two huge partners, who are both great at what they do.
~ The mtr products are fairly risk free. They are showing slightly improved effecacy, but have much less side effects than their relevant chemo drugs.
~ acl's other technologies are showing good results, & are progressing.
~ The company is cashed up.
~ The are an obvious takeover target. infact that might be the reason for the reduced sp, as an interested party is bringing the sp down, pre bid. I don't actually think that is happening though.
~ All brokers who cover acl have it as a buy. With price ranges from $1.80's to Bioshares's $10+. Momenta in the US, who are probably the best yardstick to compare acl with, are valued at US$428. This is despite price weakness caused by an impending court case regarding patent issues.
buy & hold
- Forums
- ASX - By Stock
- TSN
- broker prediction
broker prediction, page-4
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable